Session » (2079–2105) Osteoarthritis – Clinical Poster II

Date: Tuesday, October 28, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 2088

Aging Unevenly: National Trends and Inequities in Osteoarthritis Mortality, 1999–2020

10:30AM-12:30PM: Abstract Number: 2079

Association Between Symptomatic Knee Osteoarthritis and Health-Related Quality of Life in Individuals with Type 2 Diabetes: A Cross-Sectional Study

10:30AM-12:30PM: Abstract Number: 2093

Association of Acetaminophen Use with Clinical Outcomes in Older Adults with Osteoarthritis: A Global Propensity-Matched Retrospective Cohort Analysis

10:30AM-12:30PM: Abstract Number: 2092

Associations Among Biomarkers, Cytokines, and Ultrasound Features of Knee Osteoarthritis: A Cross-Sectional Analysis in the Johnston County Health Study

10:30AM-12:30PM: Abstract Number: 2102

Construct Validity of the Six-Minute Walk Test in Knee Osteoarthritis

10:30AM-12:30PM: Abstract Number: 2087

Does Carbamazepine Impact Risk of Developing Osteoarthritis? Results of a Real-World Data Analysis

10:30AM-12:30PM: Abstract Number: 2090

Don’t Throw Out X-Rays! Radiographic Osteoarthritis Severity is Prognostic for Onset of Frequent Knee Pain

10:30AM-12:30PM: Abstract Number: 2085

Estimating the Association between Effusion-synovitis and Knee Pain in a Subset of Participants with Radiographic Knee Osteoarthritis: Data from the Osteoarthritis Initiative (OAI)

10:30AM-12:30PM: Abstract Number: 2094

Evaluating the Accuracy of Knee Acoustic Emissions Classification of Varus Thrust

10:30AM-12:30PM: Abstract Number: 2083

Evaluation of a Parent-Trial as a Run-In Period: Efficacy and Safety of Repeat Injections of Lorecivivint over Three Years

10:30AM-12:30PM: Abstract Number: 2080

Foot laterality does not modify outcome of knee and/or hip osteoarthritis

10:30AM-12:30PM: Abstract Number: 2096

Gamification and Social Incentivization to Promote Physical Activity in Adults with Knee Osteoarthritis: Results from a Multi-Site Randomized Trial

10:30AM-12:30PM: Abstract Number: 2099

Incidence and Prevalence of Osteoarthritis in the United States Compared to Global Trends: Insights from the Global Burden of Disease Study (1990–2021)

10:30AM-12:30PM: Abstract Number: 2101

LEVI-04, a Novel Neurotrophin-3 Inhibitor, Demonstrates Clinically Meaningful Improvements in Pain and Physical Function across a Range of OA Outcomes, Including the Staircase-Evoked Pain Procedure (StEPP)

10:30AM-12:30PM: Abstract Number: 2091

Multiplanar MRI Quantification of Effusion-Synovitis: Reliability and Potential Investigative Utility for Inflammation-Mediated Knee Conditions

10:30AM-12:30PM: Abstract Number: 2104

Pain 0-10 visual analog scale (VAS) and RAPID3 (routine assessment of patient index data) in OA and RA are similar in 2024 to 1979 and 1989

10:30AM-12:30PM: Abstract Number: 2103

PCRX-201 High-Capacity Adenovirus Serotype 5 Gene Therapy Demonstrates Sustained Clinical Efficacy and Safety in Patients With Knee Osteoarthritis

10:30AM-12:30PM: Abstract Number: 2082

Pharmacokinetic Profile of MM-II Following a Single Intra-Articular Injection in Patients with Knee Osteoarthritis in a Phase 2b Randomized, Controlled, Dose-Ranging Trial

10:30AM-12:30PM: Abstract Number: 2084

Predictors of Change in Physical Activity Level Among Veterans with Knee Osteoarthritis in a Behaviorally Designed Incentive Program

10:30AM-12:30PM: Abstract Number: 2081

Radiologic surveillance in the Phase II RCT of LEVI-04, a novel neurotrophin-3 inhibitor, in people with knee osteoarthritis: exclusions at screening

10:30AM-12:30PM: Abstract Number: 2098

Responder Phenotype Analysis for Intra-Articular Injections: Secondary Analysis from a Large Multi-Site Crossover Clinical Trial

10:30AM-12:30PM: Abstract Number: 2105

Stratification for elevated urate identifies a pro-inflammatory synovial fluid proteome in knee osteoarthritis: a pilot study

10:30AM-12:30PM: Abstract Number: 2100

Trabecular Bone Texture is Associated with Structural and Pain Progression in Later Stages of Knee Osteoarthritis: Longitudinal Data from the FNIH OAI Cohort

10:30AM-12:30PM: Abstract Number: 2089

Traction Therapy May Improve Hand Function in Those with Distal Interphalangeal Osteoarthritis

10:30AM-12:30PM: Abstract Number: 2097

Trajectories of psychological symptoms during an 18-month Diet + Exercise intervention in overweight or obese adults with osteoarthritis

10:30AM-12:30PM: Abstract Number: 2095

Trends in Mortality and Disability-Adjusted Life Years (DALYs) from Osteoarthritis in the United States Compared to Global Estimates: A GBD-Based Analysis (1990–2021)

10:30AM-12:30PM: Abstract Number: 2086

WOMAC Physical Function and 3D MRI Bone Shape: Advancing a “Virtual” Total Knee Replacement Endpoint for Knee Osteoarthritis Clinical Trials

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].